After the successful launch of its sepsis diagnostics portfolio, SIRS-Lab raises fresh capital to build up its sales and marketing organization

SIRS-Lab announced the clos­ing of a fol­low up financ­ing round led by Affen­tranger Asso­ciates SA along­side with bm|t beteili­gungs­man­age­ment thürin­gen gmbh. This new round aims at a rapid ramp up of SIRS-Lab’s sales and mar­ket­ing organization.

Sep­sis is the 2^nd cause of death in hos­pi­tals after car­dio-vas­cu­lar dis­ease with more than 2 mil­lions cases per year. Lim­ited viable and fast diag­nos­tic meth­ods are cur­rently avail­able. SIRS-Lab, a lead­ing mol­e­c­u­lar diag­nos­tic com­pany in the field of life-threat­en­ing infec­tions, obtained fur­ther fund­ing to expand and fur­ther com­mer­cial­ize its break­through sep­sis diag­nos­tic suite com­posed of two unique prod­ucts VYOO and SIQNATURE.

“With the strong back­ing of our exist­ing investor group, we can carry for­ward the cur­rent strong momen­tum at SIRS-Lab” says bm|t’s CEO Dr. Guido Bohnenkamp. “The unique diag­nos­tics devel­oped by SIRS-Lab address the unmet med­ical need of early sep­sis detec­tion and are get­ting strong trac­tion in the mar­ket; the lat­est financ­ing round will allow the com­pany to invest in the com­mer­cial orga­ni­za­tion to accel­er­ate this adop­tion process across the world.” adds Nico­las Fulpius, Chair­man of the board of SIRS-Lab and Part­ner at Affen­tranger Associates.

VYOO – an IQ Inno­va­tion award win­ning test – is a cut­ting-edge pathogen detec­tion test that enables physi­cians to deter­mine the causative agent of a deadly infec­tion much ear­lier and more reli­ably than cur­rently pos­si­ble. SIQNATURE was recently pre­sented to the sci­en­tific com­mu­nity at the “Inter­na­tional Shock Soci­ety” con­gress in Cologne. The break­through immune mon­i­tor­ing test allows early detec­tion of sep­sis and mon­i­tor­ing of patients at risk. VYOO is avail­able for pur­chase since Decem­ber 2007; SIQNATURE will be mar­keted start­ing in Q4 2008.

Sepsis

Sep­sis is a life-threat­en­ing sys­temic infec­tion and one of the main causes of death in hos­pi­tals world­wide. Per year, around 2 Mio peo­ple suf­fer from the dis­ease in indus­trial coun­tries alone. 50% of the patients die. Sep­sis fur­ther con­sumes a major part of health care resources. Mol­e­c­u­lar diag­nos­tic solu­tions meet the cur­rently unmet med­ical needs of fast and reli­able iden­ti­fi­ca­tion of sepsis.

About SIRS-Lab

Located in Jena, Ger­many, SIRS-Lab is a mol­e­c­u­lar diag­nos­tic com­pany devel­op­ing unique and inno­v­a­tive prod­ucts to iden­tify and mon­i­tor life-threat­en­ing infec­tions as sep­sis, one of the major cause of death in hos­pi­tals. Cre­ated as a spin-off of the Uni­ver­sity Klinik of Jena, SIRS-Lab was founded in 2000 by S. Russ­wurm, K. Rein­hart, E. Straube, and H.-P. Saluz and cur­rently employs 50 people.

About Affentranger Associates SA

Incor­po­rated in 2002, Affen­tranger Asso­ciates is a Switzer­land based busi­ness plat­form focused on the theme of value cre­ation and active man­age­ment. As prin­ci­pal investor, the com­pany has the ambi­tion to achieve sus­tain­able long-term returns by invest­ing a com­bi­na­tion of man­age­ment and cap­i­tal in high-growth poten­tial com­pa­nies. Affen­tranger Asso­ciates has offices in Geneva and Zurich.

Press Contact

SIRS-Lab GmbH
Dr. Ste­fan Russ­wurm — CEO

Winz­er­laer Strasse 2
D‑07745 Jena
Germany
+49 (0) 3641 508–430
 www.sirslab.com

Affen­tranger Asso­ciates SA
Nico­las Fulpius

100 rue du Rhône
1204 Geneva
Switzerland
+41 228 180–180
 www.aasa.com